Luteinizing Hormone (LH) Ovulation

Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Luteinizing Hormone (hLH) in human urine. For Near-patient in vitro diagnostic use only.

Intended Use:

Biocan luteinizing hormone (LH) Ovulation Test is a rapid and convenient immunochromatographic in vitro assay for the detection of human LH in urine to predict when there is a LH surge, and in turn, when you are likely to ovulate. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of ovulation.  Results with the Biocan luteinizing hormone (LH) Ovulation Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For Near-patient in vitro diagnostic use only.

Summary and Principle:

Luteinizing hormone is always present in human urine. LH increases dramatically just before women's most fertile day of the month in a process commonly referred to as the "LH Surge" This LH increase triggers ovulation, which means an egg is released from woman's ovary. Because the egg can be fertilized only 6 to 24 hours after ovulation, detecting ovulation in advance by testing for the LH surge is very important for women seeking pregnancy. The best times to test are between 11am and 3pm and 5pm and 10pm. Early morning testing is not recommended as it does not show up in the urine until later in the day. If you want to make sure that you catch your surge, you may test twice a day, once in the earlier time frame and the other in the later time frame. When to begin testing: The test can be done at any time of the day, preferably after 10am and before 8pm. If testing twice a day, testing at least 8 hours apart will help catch shorter LH surges. Test should be done at approximately the same time each day. Reduce liquid intake for 2 hours before testing. To find out when to begin testing, determine the length of normal period cycle. The length of cycle is from the beginning of one period (the day of first bleeding) to the day before the beginning of the next. Count the first day of bleeding or spotting as day one (1). If the cycle length is irregular, that is, if it varies by more than a few days each month take the average number of days for the last 3 months. Use the chart shown to work out the day you should begin testing. The day you begin testing is posted opposite the number of days in your normal cycle.    

Length of Normal Cycle (Total days)

Start testing this many days after your last period began.

Length of Normal Cycle (Total days)

Start testing this many days after your last period began.

21

22

23

24

25

26

27

28

29

30

5

5

6

7

8

9

10

11

12

13

31

32

33

34

35

36

37

38

39

40

14

15

16

17

18

19

20

21

22

23

Luteinizing Hormone (LH) Ovulation

Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Luteinizing Hormone (hLH) in human urine. For Near-patient in vitro diagnostic use only.

Intended Use:

Biocan Tell Me Fast luteinizing hormone (LH) Ovulation Test is a rapid and convenient immunochromatographic in vitro assay for the detection of human LH in urine to predict when there is a LH surge, and in turn, when you are likely to ovulate. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of ovulation.  Results with the Biocan Tell Me Fast luteinizing hormone (LH) Ovulation Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For Near-patient in vitro diagnostic use only.

Summary and Principle:

Luteinizing hormone is always present in human urine. LH increases dramatically just before women's most fertile day of the month in a process commonly referred to as the "LH Surge" This LH increase triggers ovulation, which means an egg is released from woman's ovary. Because the egg can be fertilized only 6 to 24 hours after ovulation, detecting ovulation in advance by testing for the LH surge is very important for women seeking pregnancy. The best times to test are between 11am and 3pm and 5pm and 10pm. Early morning testing is not recommended as it does not show up in the urine until later in the day. If you want to make sure that you catch your surge, you may test twice a day, once in the earlier time frame and the other in the later time frame. When to begin testing: The test can be done at any time of the day, preferably after 10am and before 8pm. If testing twice a day, testing at least 8 hours apart will help catch shorter LH surges. Test should be done at approximately the same time each day. Reduce liquid intake for 2 hours before testing. To find out when to begin testing, determine the length of normal period cycle. The length of cycle is from the beginning of one period (the day of first bleeding) to the day before the beginning of the next. Count the first day of bleeding or spotting as day one (1). If the cycle length is irregular, that is, if it varies by more than a few days each month take the average number of days for the last 3 months. Use the chart shown to work out the day you should begin testing. The day you begin testing is posted opposite the number of days in your normal cycle.    

Length of Normal Cycle (Total days)

Start testing this many days after your last period began.

Length of Normal Cycle (Total days)

Start testing this many days after your last period began.

21

22

23

24

25

26

27

28

29

30

5

5

6

7

8

9

10

11

12

13

31

32

33

34

35

36

37

38

39

40

14

15

16

17

18

19

20

21

22

23

Human Chorionic Gonadotropin (Pregnancy) Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human urine. For near-patient in vitro diagnostic use only.

(Midstream)

Intended Use:

Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in urine for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in urine provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is 20 mIU/ml hCG. Urine samples equal to or greater than 20 mIU/ml will be tested positive.  Samples containing less than 20 mIU/ml hCG may also produce a very faint positive line.

Human Chorionic Gonadotropin (Pregnancy) Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human urine. For near-patient in vitro diagnostic use only.

(Cassette/Strip)  

Intended Use:

Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in urine for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in urine provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is 20 mIU/ml hCG. Urine samples equal to or greater than 20 mIU/ml will be tested positive.  Samples containing less than 20 mIU/ml hCG may also produce a very faint positive line.

hCG (Pregnancy) Serum/Urine Combo Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human urine/serum. For near-patient in vitro diagnostic use only.

(Cassette/Strip)  

Intended Use:

Biocan hCG (Pregnancy) Serum/Urine Combo Rapid Test is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in urine/serum for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan hCG (Pregnancy) Serum/Urine Combo Rapid Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in urine/serulm provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the hCG (Pregnancy) Serum/Urine Combo Rapid Test is 20 mIU/ml hCG. Urine/serum samples equal to or greater than 20 mIU/ml will be tested positive.  Samples containing less than 20 mIU/ml hCG may also produce a very faint positive line.

hCG Ultrasensitive Early Detection Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human urine. For near-patient in vitro diagnostic use only.

(Midstream)

Intended Use:

Biocan hCG Ultrasensitive Early Detection Rapid Test is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in urine for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan hCG Ultrasensitive Early Detection Rapid Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in urine provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. hCG Ultrasensitive Early Detection Rapid Test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the hCG Ultrasensitive Early Detection Rapid Test is 10 mIU/ml hCG. Urine samples equal to or greater than 10 mIU/ml will be tested positive.  Samples containing less than 10 mIU/ml hCG may also produce a very faint positive line.

hCG Ultrasensitive Early Detection Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human urine. For near-patient in vitro diagnostic use only.

(Cassette/Strip)

Intended Use:

Biocan hCG Ultrasensitive Early Detection Rapid Test is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in urine for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan hCG Ultrasensitive Early Detection Rapid Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in urine provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. hCG Ultrasensitive Early Detection Rapid Test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the hCG Ultrasensitive Early Detection Rapid Test is 10 mIU/ml hCG. Urine samples equal to or greater than 10 mIU/ml will be tested positive.  Samples containing less than 10 mIU/ml hCG may also produce a very faint positive line.

Human Chorionic Gonadotropin (Pregnancy) Rapid Test

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human serum/plasma/whole blood. For near-patient in vitro diagnostic use only.

(Cassette/Strip)

Intended Use:

Biocan Human Chorionic Gonadotropin (Pregnancy) Rapid Test is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in serum/plasma/whole blood for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan Human Chorionic Gonadotropin (Pregnancy) Rapid Test must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in serum/plasma/whole blood provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. Human Chorionic Gonadotropin (Pregnancy) Rapid Test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the Human Chorionic Gonadotropin (Pregnancy) Rapid Test is 20 mIU/ml hCG. Serum/plasma/whole blood samples equal to or greater than 20 mIU/ml will be tested positive.  Samples containing less than 20 mIU/ml hCG may also produce a very faint positive line.

hCG(Pregnancy) Ultrasensitive Early Detection Combo

CE APPROVED

 

A rapid test for the qualitative detection of Human Chorionic Gonadotropin (hCG) in human urine/serum. For near-patient in vitro diagnostic use only.

(Cassette/Strip)

Intended Use:

Biocan hCG(Pregnancy) Ultrasensitive Early Detection Combo is a rapid and convenient immunochromatographic in vitro assay. It is used for the detection of Human hCG hormone in urine/serum for early diagnosis of pregnancy. It is intended to be used as a preliminary screening test and as an aid in the diagnosis of Pregnancy.  Results with the Biocan hCG(Pregnancy) Ultrasensitive Early Detection Combo must be confirmed with alternative testing method (s) and clinical findings. This is a screening test and not a confirmatory test. For near-patient in vitro diagnostic use only.

Summary and Principle:

hCG is a hormone produced by trophoblastic tissue and it appears around the 8-9th day after ovulation, or around the 4th day after conception. In a 28 day cycle with ovulation occurring at day 14, hCG can be detected in urine or serum in minute quantities around day 23, or 5 days before the expected menstruation. The hormone concentration doubles approximately every 2 days and peaks between 7-12 weeks after the first day of the last menstrual period. In normal subjects, hCG in urine/serum provides an early indication of pregnancy. The elevated hCG levels are also associated with trophoblastic diseases and certain nontrophoblastic neoplasms. Thus, the possibility of other diseases must be eliminated before the diagnosis of pregnancy can be made. HCG consists of two subunits, alpha and beta. Alpha subunits of these various glycoprotein hormones are structurally very similar, but beta subunits differ in amino acid sequences. These differences are responsible for their biological and immunological specificity. Tell Me Fast human Chorionic Gonadotropin (hCG) Pregnancy test is based on the principle of immunochromatography. Each test device contains monoclonal anti-beta-hCG antibody / colloidal gold conjugate pre-dried on a pad.  Monoclonal anti-alpha-hCG antibody (at the test region) and goat anti mouse IgG  (at the control region) are coated on the membrane.  When the absorbent pad is soaked with urine, the urine will migrate via capillary action toward the result window.  If hCG is present in the urine, it reacts with anti-beta-hCG antibody / colloidal gold conjugate to form a complex which will move and be captured by anti-alpha-hCG antibodies to form a colored line in the test region.  The control line is not influenced by the presence or absence of hCG in sample, and it should be present in all reactions. Absence of a colored control line in the control region is an indication of an invalid result. The detection limit for the hCG(Pregnancy) Ultrasensitive Early Detection Combo is 10 mIU/ml hCG. Urine samples equal to or greater than 10 mIU/ml will be tested positive.  Samples containing less than 10 mIU/ml hCG may also produce a very faint positive line.

Product dispayed are not for sale in Canada Biocan Diagnostics Inc. © 2018. All rights reserved.